The Tamiflu and Ozempic labels do not list a direct interaction between the two medicines. A clinician reviews the person's medicines and illness to decide whether to use them together. Both can cause nausea or vomiting, though. The important questions are whether fluids stay down, how the kidneys are working, and whether the illness needs flu treatment.

Tamiflu is oseltamivir, a prescription antiviral medicine that acts against flu viruses. Ozempic contains semaglutide. Nausea during semaglutide treatment does not, by itself, mean someone has flu.

Tamiflu and Ozempic: what the labels actually say

As of November 20, 2026, the day this article was written, the Ozempic injection label carries “Revised: 05/2026.” It warns that delayed gastric emptying, meaning slower movement of food out of the stomach, can affect medicines swallowed by mouth. It calls for caution, but does not name oseltamivir.

The Tamiflu label, marked “Revised: 8/2019,” does not name semaglutide either. Neither label supplies a waiting gap that makes this particular combination safe for everyone.

There is useful background research, with a clear limit. In Hausner and colleagues' 2017 study in Clinical Pharmacokinetics, injected semaglutide did not meaningfully change overall blood exposure to four tested medicines. Blood exposure means how much medicine reaches the bloodstream over time. The medicines were for diabetes, blood clotting, cholesterol and heart problems. Oseltamivir was not tested.

Those results cannot settle the Tamiflu question. They do show why slower stomach emptying alone is not proof that every swallowed medicine stops working.

Flu treatment depends on the illness, not just the medicine list

Influenza, or flu, is a respiratory infection, usually involving a sudden cough, fever or chills, and body aches. The illness often called “stomach flu” is a different problem. The guide to a stomach bug during GLP-1 treatment covers that distinction. GLP-1 medicines, including semaglutide, mimic a gut hormone involved in fullness and blood sugar.

As of November 20, 2026, the day this article was written, CDC's flu-and-diabetes guidance, updated September 1, 2026, recommends prompt antiviral treatment for people with diabetes and suspected flu. It says people with diabetes who develop flu symptoms should contact their healthcare provider right away.

As of November 20, 2026, the day this article was written, CDC's clinician guidance, updated March 10, 2026, says treatment should not wait for test confirmation in priority groups. These include hospitalized people, those with severe or worsening illness, and those at higher risk of complications. For otherwise healthy outpatients, clinicians may consider treatment within 2 days of symptom onset.

That is a treatment window, not a Tamiflu dosing schedule. A positive test is not always required, and the 2-day point is not a universal cutoff for severe illness.

Tamiflu nausea with semaglutide: overlap is not proof of an interaction

Both medicines list nausea and vomiting. An episode after starting Tamiflu could reflect that medicine, semaglutide, the infection, or more than one cause.

In the Tamiflu label's adult and adolescent treatment trials, about 10 in 100 people reported nausea, versus 6 in 100 on placebo. Placebo is the inactive comparison treatment. Vomiting occurred in 8 in 100 versus 3 in 100. Those figures describe Tamiflu trials, not people taking this pair together.

In Treanor and colleagues' JAMA trial, published in 2000, 629 previously healthy adults were assigned by chance to oseltamivir or placebo. Nausea and vomiting were more common in the oseltamivir groups. That trial did not test semaglutide.

Symptoms alone cannot identify a direct interaction. Whether liquids stay down and whether symptoms are getting worse matter to the illness review. Adding an antiviral also creates a different question from choosing a cough remedy; the cold-medicine guide covers those ingredients.

Why fluid loss and kidney function matter

Dehydration means the body has too little fluid. The Ozempic label describes reports of sudden kidney injury, sometimes requiring dialysis, mostly after nausea, vomiting or diarrhea caused dehydration. It tells clinicians to “Monitor renal function,” meaning check how well the kidneys work, when side effects could cause fluid loss.

The Medication Guide says to tell the provider about stomach problems that are severe or will not go away. For nausea, vomiting or diarrhea that will not go away, it says to contact the provider right away. Difficulty keeping liquids down belongs in that contact, rather than waiting for a routine follow-up.

Kidney function also affects oseltamivir levels. The Tamiflu label recommends dose adjustment for some people with reduced kidney function or receiving dialysis, a treatment that filters blood. It does not recommend Tamiflu for people with end-stage kidney disease who are not receiving dialysis. The prescriber sets the dose; a semaglutide prescription does not answer that kidney question.

The vaccine interaction is a separate issue

Tamiflu's vaccine warning concerns the live nasal flu vaccine, which contains weakened viruses. The label says to avoid that vaccine within 2 weeks before or 48 hours after Tamiflu, unless medically indicated. Oseltamivir could interfere with the vaccine virus.

The label allows an inactivated flu vaccine, made without live virus, at any time relative to Tamiflu. That is different from proving every vaccine suitable for every person. CDC generally recommends the shot rather than the nasal vaccine for people with diabetes.

The flu-shot guide for people taking semaglutide covers prevention. The nasal-vaccine warning does not establish an interaction between Tamiflu and Ozempic.

Semaglutide during flu: the prescriber sets the illness plan

Neither label directs an automatic semaglutide pause just because Tamiflu was prescribed. The clinician considers the illness, fluid intake, other diabetes medicines and the actual semaglutide product. Flu can raise blood sugar, while poor intake can bring it down in someone with diabetes.

Ozempic's label warns that persistent or severe belly pain can signal pancreatitis, meaning inflammation of the pancreas. Pain can spread to the back, with or without nausea or vomiting. Some cases have been fatal. The label directs clinicians to stop Ozempic and start appropriate care if they suspect pancreatitis. Its Medication Guide says to stop Ozempic and call the provider right away for severe belly pain that will not go away.

Tamiflu is contraindicated, meaning it must not be used, after a known serious allergy to oseltamivir or another ingredient. Its patient information directs stopping Tamiflu and getting medical help right away for rash, blistering, facial swelling or breathing trouble.

The Tamiflu label also warns of reports of delirium and abnormal behavior leading to injury, in some cases fatal, mainly in children with flu; flu itself can cause these symptoms, and Tamiflu's part has not been established. Its patient information says to tell the healthcare provider right away about confusion, speech problems, shaky movements, seizures or hallucinations during treatment.

Brand information and a compounded prescription

Compounding means a pharmacy prepares a medication for a prescription. Semaglutide prescribed through Promise is dispensed by a licensed U.S. compounding pharmacy as a compounded medication, which is different from an FDA-approved product: the formulation offered here is not FDA-approved. As of November 20, 2026, the day this article was written, FDA's September 16, 2025 Q&A explains that compounded drugs do not undergo its review for safety, effectiveness or quality before marketing.

A licensed provider may still prescribe — that decision is between you and your doctor.

What belongs in the clinical review

The useful details are the exact medicines, when flu symptoms started, the last semaglutide dose, any recent dose increase, kidney history and whether fluids stay down. For diabetes, recent blood-sugar readings help too.

At Promise, a licensed provider reviews every request, and not everyone qualifies. The semaglutide product page connects that review to the specific prescription. An illness plan belongs with the clinician who knows the person's treatment.